Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.39 |
| ▸ | MAOB | P27338 | 4/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.34 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29673201 | 1.00 | MAOA (0.39) | MAOAMAOBCYP2A6PRKCINOTUM | |
| SCHEMBL30666511 | 0.88 | NOTUM (0.44) | NOTUMHSD17B1MAPK14HSD17B10KDM4E | |
| SCHEMBL1339423 | 0.88 | NOTUM (0.44) | NOTUMHSD17B1MAPK14HSD17B10KDM4E | |
| SCHEMBL14053140 | 0.82 | MAOA (0.38) | MAOAMAOBCYP2A6PRKCIHSD17B1 | |
| SCHEMBL22253606 | 0.81 | MAOA (0.41) | MAOAMAOBCYP2A6PRKCIPARP1 | |
| SCHEMBL4637638 | 0.81 | MAOA (0.37) | MAOAMAOBCYP2A6PRKCIPARP1 | |
| SCHEMBL6121207 | 0.81 | KDM4E (0.41) | MAOAMAOBCYP2A6PRKCIPARP1 | |
| SCHEMBL24542979 | 0.81 | NOTUM (0.41) | MAOAMAOBCYP2A6PRKCINOTUM | |
| SCHEMBL30070449 | 0.81 | MAOA (0.37) | MAOAMAOBCYP2A6PRKCIPARP1 | |
| SCHEMBL29673139 | 0.81 | NOTUM (0.41) | MAOAMAOBCYP2A6PRKCINOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022132200-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022127827-A1 | KRASG12C PROTEIN MUTATION INHIBITOR AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | 上海维申医药有限公司 | 2022-06-23 | — | — | WO | disclosed |
| EP-2714675-B1 | 4H-THIENO[3,2-C]CHROMENE-BASED INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2019-01-02 | — | — | EP | disclosed |
| EP-2714675-B1 | 4H-THIENO[3,2-C]CHROMENE-BASED INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2019-01-02 | — | — | EP | disclosed |
| US-9624238-B2 | 4H-thieno[3,2-C]chromene-based inhibitors of Notum Pectinacetylesterase and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624238-B2 | 4H-thieno[3,2-C]chromene-based inhibitors of Notum Pectinacetylesterase and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624238-B2 | 4H-thieno[3,2-C]chromene-based inhibitors of Notum Pectinacetylesterase and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20140256784-A1 | 4H-THIENO[3,2-C]CHROMENE-BASED INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2014-09-11 | — | — | US | disclosed |
| US-20140256784-A1 | 4H-THIENO[3,2-C]CHROMENE-BASED INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2014-09-11 | — | — | US | disclosed |
| US-20140256784-A1 | 4H-THIENO[3,2-C]CHROMENE-BASED INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2014-09-11 | — | — | US | disclosed |
| US-20120302562-A1 | 4H-THIENO[3,2-C]CHROMENE-BASED INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20120302562-A1 | 4H-THIENO[3,2-C]CHROMENE-BASED INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20120301514-A1 | DEVELOPMENT OF BIOACTIVE ELECTROSPUN COATINGS FOR BIOMEDICAL APPLICATIONS | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2012-11-29 | — | — | US | disclosed |
| US-20120302562-A1 | 4H-THIENO[3,2-C]CHROMENE-BASED INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20080306045-A1 | 1-Benzazepine-3-Sulfonylamino-2-Pyrroridones as Factor Xa Inhibitors | CAMUS LAURE | 2008-12-11 | — | — | US | disclosed |
| US-20080306045-A1 | 1-Benzazepine-3-Sulfonylamino-2-Pyrroridones as Factor Xa Inhibitors | CAMUS LAURE | 2008-12-11 | — | — | US | disclosed |
| US-20080306045-A1 | 1-Benzazepine-3-Sulfonylamino-2-Pyrroridones as Factor Xa Inhibitors | CAMUS LAURE | 2008-12-11 | — | — | US | disclosed |
| EP-1951712-A2 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007059952-A2 | 1-BENZAZEPINE-3-SULFONYLAMINO-2-PYRRLORIDONES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007059952-A2 | 1-BENZAZEPINE-3-SULFONYLAMINO-2-PYRRLORIDONES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256784-A1 | 4H-THIENO[3,2-C]CHROMENE-BASED INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | NOTUM, CES1, ACHE | MAOA 1891/4885MAOB 1721/4885CYP2A6 332/4885 |
| US-20120302562-A1 | 4H-THIENO[3,2-C]CHROMENE-BASED INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | NOTUM, CES1, ACHE | MAOA 1891/4885MAOB 1721/4885CYP2A6 332/4885 |
| US-20080306045-A1 | 1-Benzazepine-3-Sulfonylamino-2-Pyrroridones as Factor Xa Inhibitors | TFPI, TPSAB1, TFPI2 | MAOA 208/4885MAOB 182/4885CYP2A6 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.